{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:50:39Z","timestamp":1762113039199,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81603204"],"award-info":[{"award-number":["81603204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.cbi.2021.109775","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T13:31:03Z","timestamp":1639315863000},"page":"109775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Inhibition of cytochrome P450 enzymes and uridine 5\u2032-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions"],"prefix":"10.1016","volume":"352","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-0330","authenticated-orcid":false,"given":"Shuaibing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziteng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-9072","authenticated-orcid":false,"given":"Eric","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.cbi.2021.109775_bib1","first-page":"e574","article-title":"2011ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American college of cardiology foundation\/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cbi.2021.109775_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vph.2016.05.010","article-title":"Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors","volume":"84","author":"Thomas","year":"2016","journal-title":"Vasc. Pharmacol."},{"issue":"6","key":"10.1016\/j.cbi.2021.109775_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/09537104.2014.959913","article-title":"Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects","volume":"26","author":"Guo","year":"2015","journal-title":"Platelets"},{"issue":"4","key":"10.1016\/j.cbi.2021.109775_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cbi.2021.109775_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(92)90445-O","article-title":"Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel","volume":"44","author":"Savi","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.cbi.2021.109775_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.cbi.2021.109775_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11095-013-1158-5","article-title":"Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel","volume":"31","author":"Qiu","year":"2014","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.cbi.2021.109775_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fphar.2017.00846","article-title":"Arylacetamide deacetylase is involved in vicagrel bioactivation in humans","volume":"8","author":"Jiang","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.cbi.2021.109775_bib9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/bcp.14296","article-title":"Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor","volume":"86","author":"Zhang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109775_bib10","doi-asserted-by":"crossref","first-page":"591854","DOI":"10.3389\/fphar.2020.591854","article-title":"Predicting the effects of CYP2C19 and carboxylesterases on vicagrel, a novel P2Y12 antagonist, by physiologically based pharmacokinetic\/pharmacodynamic modeling approach","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109775_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.vascn.2015.10.003","article-title":"Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition","volume":"77","author":"Dahlinger","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"10.1016\/j.cbi.2021.109775_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.cbi.2021.109775_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.103.056127","article-title":"Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine","volume":"308","author":"Richter","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.cbi.2021.109775_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/dmd.108.022988","article-title":"Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel","volume":"37","author":"Nishiya","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.cbi.2021.109775_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","article-title":"Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation","volume":"77","author":"Turpeinen","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.cbi.2021.109775_bib16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions","volume":"96","author":"Tornio","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2021.109775_bib17","article-title":"Pharmacokinetics, mass balance, and metabolism of [(14)C]vicagrel, a novel irreversible P2Y12 inhibitor in humans","author":"Zheng","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.cbi.2021.109775_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.cbi.2021.109775_bib19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2174\/1389200023336992","article-title":"Complexities of glucuronidation affecting in vitro in vivo extrapolation","volume":"3","author":"Lin","year":"2002","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.cbi.2021.109775_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2018.10.011","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing","volume":"127","author":"Liu","year":"2019","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.cbi.2021.109775_bib21","doi-asserted-by":"crossref","first-page":"122891","DOI":"10.1016\/j.jchromb.2021.122891","article-title":"Mass spectrometry-based targeted proteomics method for the quantification of clinically relevant drug metabolizing enzymes in human specimens","volume":"1180","author":"Wenzel","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cbi.2021.109775_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpba.2019.05.006","article-title":"Development and validation of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by HPLC-MS\/MS-based targeted proteomics","volume":"173","author":"Grangeon","year":"2019","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"4","key":"10.1016\/j.cbi.2021.109775_bib23","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/cpt.2097","article-title":"Quantification of proteins involved in intestinal epithelial handling of xenobiotics","volume":"109","author":"Al-Majdoub","year":"2021","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721004130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721004130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:49:21Z","timestamp":1762112961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279721004130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":23,"alternative-id":["S0009279721004130"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109775","relation":{},"ISSN":["0009-2797"],"issn-type":[{"type":"print","value":"0009-2797"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of cytochrome P450 enzymes and uridine 5\u2032-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109775"}}